Exchange: NASDAQ·Updated 04:43 PM EDT
FBRX logo

FBRXForte Biosciences Inc

$44.59
$7.22
(19.67%)
Today
Closed $43.92
$0.67
(1.53%)
After Hours
Mkt Cap$751.57M
Vol3.18M
News
all
press releases
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers EUDA Health Holdings (NASDAQ:EUDA) shares rose 22.3% to $15.2 during Friday's regular session. Forte Biosciences (NASDAQ:FBRX) shares moved upwards by 18.39% to $43.45. The market value of theirread more...
Benzinga
News Placeholder
More News
News Placeholder
TRAX Stock Hits All-Time High — What's Driving The Super Rally?
According to TheFly, HC Wainwright raised its price target on First Tracks to $44 from $30 while maintaining a ‘Buy’ rating.
Stocktwits
News Placeholder
FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data
Forte Biosciences stock soars after early-stage data show FB102 significantly improves facial depigmentation in vitiligo with a favorable safety profile.
Zacks
News Placeholder
FBRX Stock On Track For Biggest Single-Day Gains In 20 Months – What’s Behind The Super Rally?
Forte Biosciences announced results from its early-stage study for its investigational drug to treat an autoimmune skin condition.
Stocktwits
News Placeholder
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million. Forte Biosciences (NASDAQ:FBRX) stock roseread more...
Benzinga
News Placeholder
Forte Biosciences Skin Pigmentation Disorder Drug Shows Strong Efficacy, Safety In Early Study
Forte Biosciences reported positive Phase 1b vitiligo data, with FB102 showing significant facial repigmentation and favorable safety.read more...
Benzinga
News Placeholder
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved 29.6% mean FVASI...
Business Wire
News Placeholder
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing...
Business Wire
News Placeholder
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its first quarter 2026...
Business Wire
News Placeholder
Wall Street Zen Upgrades Forte Biosciences (NASDAQ:FBRX) to "Sell"
Wall Street Zen upgraded shares of Forte Biosciences from a 'strong sell' rating to a 'sell' rating in a research note on Saturday...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.